Golde T E, Estus S, Younkin L H, Selkoe D J, Younkin S G
Division of Neuropathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Science. 1992 Feb 7;255(5045):728-30. doi: 10.1126/science.1738847.
The approximately 120-kilodalton amyloid beta protein precursor (beta APP) is processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives that includes potentially amyloidogenic forms with the approximately 4-kilodalton amyloid beta protein (beta AP) at or near their amino terminus. In order to determine if these derivatives are processed in a secretory pathway or by the endosomal-lysosomal system, (i) deletion mutants that produce the normal set of carboxyl-terminal derivatives and shortened secreted derivatives were analyzed and (ii) the effect of inhibitors of endosomal-lysosomal processing was examined. In the secretory pathway, cleavage of the beta APP occurs at a single site within the beta AP to generate one secreted derivative and one nonamyloidogenic carboxyl-terminal fragment, whereas, in the endosomal-lysosomal system, a complex set of carboxyl-terminal derivatives is produced that includes the potentially amyloidogenic forms.
约120千道尔顿的β淀粉样蛋白前体(βAPP)被加工成一组复杂的8至12千道尔顿的羧基末端衍生物,其中包括在其氨基末端或附近带有约4千道尔顿β淀粉样蛋白(βAP)的潜在淀粉样生成形式。为了确定这些衍生物是通过分泌途径还是通过内体 - 溶酶体系统进行加工的,(i)分析了产生正常羧基末端衍生物组和缩短的分泌衍生物的缺失突变体,(ii)研究了内体 - 溶酶体加工抑制剂的作用。在分泌途径中,βAPP在βAP内的单个位点发生切割,产生一种分泌衍生物和一个非淀粉样生成的羧基末端片段,而在内体 - 溶酶体系统中,则产生一组复杂的羧基末端衍生物,其中包括潜在的淀粉样生成形式。